Genome Editing: An Outlook on Current & Future Medicines

Time: 9:20 am
day: Day 2 AM

Details:

• Clinical success of CRISPR-Cas9 Knockouts (KOs): Treating patients with severe disease
• Growing wave of in-vivo KOs for cardiovascular and rare diseases
• Next-gen developments for in-vivo gene correction and insertion

Speakers:

Christof Fellmann Christof Fellmann, PhD, is Head of CRISPR-X at CRISPR Therapeutics. Previously, he was a Research Investigator at Gladstone Institutes and Assistant Adj. Professor at University Read more